Berckmans René J, Lacroix Romaric, Hau Chi M, Sturk Auguste, Nieuwland Rienk
Laboratory of Experimental Clinical Chemistry, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Vesicle Observation Centre, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
J Extracell Vesicles. 2019 Nov 8;8(1):1688936. doi: 10.1080/20013078.2019.1688936. eCollection 2019.
: In 2001, we studied the presence and coagulant properties of "microparticles" in the blood of healthy humans. Since then, multiple improvements in detection, isolation and functional characterization of the now called "extracellular vesicles" (EVs) have been made, and shortcomings were identified. : To revisit the presence and function of EVs in blood from healthy humans. : Blood was collected from 20 healthy donors. EV-containing plasma was prepared according to new guidelines, and plasma was diluted to prevent swarm detection. Single EVs were measured by flow cytometry with known sensitivity of fluorescence and light scatter. The haemostatic properties of EVs were measured by thrombin-, fibrin-, and plasmin generation. Plasma concentrations of thrombin-antithrombin complexes and prothrombin fragment 1 + 2 were measured to assess the coagulation status . : Compared to 2001, the total concentrations of detected EVs increased from 190- to 264-fold. In contrast to 2001, however, EVs are non-coagulant which we show can be attributed to improvements in blood collection and plasma preparation. No relation is present between the plasma concentrations of EVs and either TAT or F1 + 2. Finally, we show that EVs support plasmin generation. : Improvements in blood collection, plasma preparation and detection of EVs reveal that results from earlier studies have to be interpreted with care. Compared to 2001, higher concentrations of EVs are detected in blood of healthy humans which promote fibrinolysis rather than coagulation.
2001年,我们研究了健康人血液中“微粒”的存在及其凝血特性。从那时起,在现在称为“细胞外囊泡”(EVs)的检测、分离和功能表征方面有了多项改进,同时也发现了一些不足之处。
为了重新审视健康人血液中EVs的存在和功能。
从20名健康供体采集血液。根据新指南制备含EVs的血浆,并对血浆进行稀释以防止群体检测。通过具有已知荧光和光散射灵敏度的流式细胞术测量单个EVs。通过凝血酶、纤维蛋白和纤溶酶生成来测量EVs的止血特性。测量凝血酶 - 抗凝血酶复合物和凝血酶原片段1 + 2的血浆浓度以评估凝血状态。
与2001年相比,检测到的EVs总浓度增加了190至264倍。然而,与2001年不同的是,EVs不具有凝血作用,我们发现这可归因于血液采集和血浆制备方面的改进。EVs的血浆浓度与凝血酶 - 抗凝血酶复合物(TAT)或凝血酶原片段1 + 2(F1 + 2)均无关联。最后,我们表明EVs支持纤溶酶生成。
血液采集、血浆制备和EVs检测方面的改进表明,早期研究结果必须谨慎解读。与2001年相比,在健康人血液中检测到更高浓度的EVs,这些EVs促进纤维蛋白溶解而非凝血。